<DOC>
	<DOCNO>NCT02408744</DOCNO>
	<brief_summary>The aim study evaluate impact safety efficacy new formulation prolonged-released Pirfenidone progression renal damage patient Chronic kidney Disease ( CKD ) .</brief_summary>
	<brief_title>Utility Prolonged-release Pirfenidone Progression Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>1 . Patients 10 40 year old CKD 2 . Diagnosis CKD stage 1 4 accord KDIGO definition classification 3 . No glucocorticoid , cyclophasphamide , mycophenolate , immunosuppressive drug least two month start PFD administration 4 . Sign consent form 1 . Known intolerance PFD 2 . CKD stage V accord KDOQI classification 3 . Posttransplant patient 4 . History peptic ulcer within six month 5 . History cerebrovascular disease within six month 6 . Evidence hepatic disease 7 . Pregnancy breast feed 8 . Malignancy</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>nephroprotection</keyword>
	<keyword>pirfenidone</keyword>
	<keyword>polymorphism</keyword>
</DOC>